Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Carcinoma, Intraductal, Noninfiltrating 2Mammographically Dense Breast 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 387Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Has results × afimoxifene × Clear all
NCT02993159 2024-12-18

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

Northwestern University

Phase 2 Completed
100 enrolled 15 charts
Breast

Carcinoma, Intraductal, Noninfiltrating

NCT03063619 2024-02-22

Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast

M.D. Anderson Cancer Center

Phase 2 Completed
194 enrolled 12 charts
Breast

Mammographically Dense Breast

NCT00952731 2015-07-21

4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ

Northwestern University

Phase 2 Completed
27 enrolled 12 charts
Breast

Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡